Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Titel:
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Auteur:
Choueiri, Toni K Eto, Masatoshi Motzer, Robert De Giorgi, Ugo Buchler, Tomas Basappa, Naveen S Méndez-Vidal, María José Tjulandin, Sergei Hoon Park, Se Melichar, Bohuslav Hutson, Thomas Alemany, Carlos McGregor, Bradley Powles, Thomas Grünwald, Viktor Alekseev, Boris Rha, Sun Young Kopyltsov, Evgeny Kapoor, Anil Alonso Gordoa, Teresa Goh, Jeffrey C Staehler, Michael Merchan, Jaime R Xie, Ran Perini, Rodolfo F Mody, Kalgi McKenzie, Jodi Porta, Camillo G